Paclitaxel nanosuspensions for targeted chemotherapy - Nanosuspension preparation, characterization, and use

Pharmaceutical Development and Technology

Volumn 19, Issue 4, 2014, Pages 438-453

  Lee, Sarah E ^a   Bairstow, Shawn F ^a   Werling, Jane O ^a   Chaubal, Mahesh V ^a   Lin, Lawrence ^a   Murphy, Mary Ann ^a   DiOrio, James P ^a   Gass, Jerome ^a   Rabinow, Barrett ^a   Wang, Xiaoen ^b   Zhang, Yong ^b   Yang, Zhijian ^b   Hoffman, Robert M ^b  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b ANTICANCER INC   (United States)

Author keywords

Head and neck cancer; Nanosuspension; Ovarian cancer; Paclitaxel; Targeted

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; EXCIPIENT; IMMUNOGLOBULIN; PACLITAXEL; PROTAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MATERIAL COATING; MOUSE; NANOSUSPENSION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SURFACE PROPERTY; SUSTAINED RELEASE FORMULATION; TUMOR XENOGRAFT; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELLS, CULTURED; EXCIPIENTS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; NANOPARTICLES; NIH 3T3 CELLS; OVARIAN NEOPLASMS; PACLITAXEL; SUSPENSIONS;

EID: 84899985735     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.789911     Document Type: Article

References (32)

1. Gelderblom H, Verweij J, Nooter K, et al. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-1598.
2. van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001;2:125-141.
3. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann Rev Med 1997; 48:353-374.
4. Singla AK, Garg KA, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2001;235:179-192.
5. Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J. Contr Rel 2001;72:191-202.
6. Ginsburg I, Sela MN, Morag A, et al. Role of leukocyte factors and cationic polyelectrolytes in phagocytosis of group A Streptococci and Candida albicans by neutrophils, macrophages, fibroblasts and epithelial cells. Inflammation 1981;5:289-312.
7. Tabata Y, Ikada Y. Phagocytosis of polymer microspheres by macrophages. Adv Polym Sci 1990;94:107-141.
8. Rabinow B, Bairstow S, Chaubal M, et al. Compositions and methods for drug delivery. 2010; US20100290983A1. Pub. Nov 18, 2010.
9. Ho E A, Lim Soo P, Allen C, Piquette-Miller M. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. J Contr Rel 2006;117:20-27.
10. Sugarbaker PH. Are there curative options to peritoneal carcinomatosis? Ann Surg 2005;242:748-750.
11. Haque R, Contreras R, McNicoll MP, et al. Surgical margins and survival after head and neck cancer surgery. BMC Ear Nose Throat Disord 2006;6:2-7.
12. Nag S, Koc M, Schuller DE, et al. Intraoperative single fraction high-dose-rate brachytherapy for head and neck cancers. Brachytherapy 2005;4:217-223.
13. Nag S, Schuller DE, Martinez-Monge R, et al. Intraoperative electron beam radiotherapy for previously irradiated advanced head and neck malignancies. Int J Radiat Oncol Biol Phys 1998;42: 1085-1089.
14. Pourgholami MH, Cai ZY, Lu Y, et al. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 2006;12:1928-1935.
15. Hamilton TC, Young RC, Louie KG, et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Canc Res 1984; 44:5286-5290.
16. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374:1371-1382.
17. Alberts DS, Markman M, Muggia F, et al. Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. Gynecol Oncol 2006;103:783-792.
18. Jain A, Dubashi B, Reddy KS, Jain P. Weekly paclitaxel in ovarian cancer - the latest success story. Curr Oncol 2011;18:16-17.
19. Sugarbaker PH, Mora JT, Carmignani P, et al. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005;10:112-122.
20. Lopes NM, Adams EG, Pitts TW, Bhuyan BK. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993;32:235-242.
21. Rabinow B, Kipp J, Papadopoulos P, et al. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm 2007;339:251-260.
22. Ziegler-Heitbrock L. The CD14+CD16+blood monocytes: their role in infection and inflammation. J Leuk Biol 2007;81: 584-592.
23. Strauss-Ayali D, Conrad S, Mosser D. Monocyte subpopulations and their differentiation patterns during infection. J Leuk Biol 2007;82: 244-252.
24. Gordon S, Taylor P. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-964.
25. Mantovani A, Allavena P, Sica A. Tumor-associated macrophages in cancer growth and progression. In: Prendergast GC, Jaffee EM, eds. Cancer immunotherapy. Ch.16 New York (NY): Academic Press, 2007: 289-308.
26. Grage-Griebenow E, Flad H, Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J Leuk Biol 2001;69: 11-20.
27. Armstrong DK, Bundy B, Wenzel L, et al. Gynecologic oncology group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
28. Burges A, Wimberger P, Kümper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007;13:3899-3905.
29. Baguley BC, Finlay GJ. Pharmacokinetic/cytokinetic principles in the chemotherapy of solid tumours. Clin Exp Pharmacol Physiol 1995;22:25-28.
30. Sunwoo JB, Herscher L, Kroog GS, et al. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol 2001;19:800-811.
31. Rosenthal DI, Lee JH, Sinard R, et al. Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2001;19:1363-1373.
32. De Souza R, Zahedi P, Allen CJ, Piquette-Miller M. Critical review: polymeric drug delivery systems for localized cancer chemotherapy. Drug Deliv 2010;17:365-375.